Congressional Research Service Reports - 10 Matching Results
Search Results
- The SUPPORT for Patients and Communities Act (P.L. 115-271): Food and Drug Administration and Controlled Substance Provisions
- This report summarizes the provisions in Title III--the FDA (Food and Drug Administration) and Controlled Substance Provisions, as well as Section 4004 "Modernizing the Reporting Requirements of Biological and Biosimilar Products" in Title IV--Offsets.
- Substance Abuse Prevention, Treatment, and Research Efforts in the Military
- This report discusses substance abuse trends in the military, efforts by the U.S. Department of Defense (DOD) to address the opioid crisis, and the main elements of DOD's substance abuse prevention, compliance, and disciplinary policies.
- Buprenorphine and the Opioid Crisis: A Primer for Congress
- This report addresses questions policymakers may have about the effectiveness of the opioid addiction treatment drug buprenorphine, the demand for buprenorphine, and access to buprenorphine.
- Opioid Treatment Programs and Related Federal Regulations
- This report provides information on federal regulations regarding treatment for opioid addiction, including medication-assisted treatment (MAT), opioid treatment programs (OTPs), and DATA-waived providers (DWPs).
- Increase in Illicit Fentanyl Overdose Deaths
- This report discusses fentanyl, a synthetic opioid that is 50-100 times more potent than morphine. The steep increase in overdose deaths involving fentanyl is seen as a "new chapter" in the opioid epidemic. Topics covered include the rise of fentanyl overdoses, availability of fentanyl, and policy considerations.
- The Opioid Epidemic and the Food and Drug Administration: Legal Authorities and Recent Agency Action
- This report focuses on the U.S. Food and Drug Administration (FDA) as a key player in federal efforts to curb the opioid epidemic. It provides an overview of FDA's role in approving new prescription drugs, including challenges of approval and regulation of opioid products; addresses FDA's multifaceted approach in responding, including recent agency action; and concludes with a discussion of selected opioid-related legislation in the 115th Congress.
- High Intensity Drug Trafficking Areas (HIDTA) Program
- This report provides an overview of the High Intensity Drug Trafficking Areas (HIDTA) program, including how areas are designated as part of a HIDTA, and program coordination and funding. It also examines issues that policymakers may consider as they debate the future of the program: whether the county is still an appropriate unit of inclusion, whether the criteria remain adequate, whether the program is effective, whether its tangential effects can be measured, whether the current bounds on funds are still appropriate, and which federal entity may be best suited to administer the program.
- Legal Authorities Under the Controlled Substances Act to Combat the Opioid Crisis
- This report discusses legal authorities available to the federal government under the Controlled Substances Act (CSA) that could be used to combat the opioid epidemic. The report then examines DEA initiatives and actions taken, pursuant to its legal authorities under the CSA, which specifically target the abuse of opioids. It concludes by discussing selected opioid-related legislative proposals in the 115th Congress that would amend the CSA.
- Federal Support for Drug Courts: In Brief
- This report explains the concept of a "drug court,", how the term and programs have expanded to include wider meanings and serve additional subgroups, how the federal government supports drug courts, and research on the impact of drug courts on offenders and court systems. In addition, it briefly discusses how drug courts might provide an avenue for addressing the opioid epidemic and other emerging drug issues that Congress may consider.
- Responding to the Opioid Epidemic: Legal Developments and FDA's Role
- This report discusses the opioid epidemic in the U.S. and the role of the Federal Food and Drug Administration (FDA) in helping end the epidemic. The report provides an overview of FDA's existing authorities, the historical context for the opioid epidemic, and the agency's current plan for combatting the opioid epidemic, concluding with an examination of the broader legal questions concerning the crisis.